NCT06862219View on ClinicalTrials.gov

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 21, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Metastatic Urothelial Carcinoma
Interventions
DRUG

Enfortumab Vedotin

Intravenous Infusion

Trial Locations (7)

Unknown

RECRUITING

Site IN91017, Dumas

RECRUITING

Site IN91005, Varanasi

RECRUITING

Site IN91012, Ahmedabad

RECRUITING

Site IN91010, Bhubaneswar

RECRUITING

Site IN91008, Mumbai

RECRUITING

Site IN91009, Nagpur

RECRUITING

Site IN91001, Surat

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

collaborator

Pfizer

INDUSTRY